Curiously, in the last decade the potential function of SIGMAR1 in cancer has gained increasing interest as a potential new biomarker, as previously demonstrated in breast cancer [9], colorectal cancer [10], and prostate cancer [11]. This evidence concerns the gene SIGMAR1 and prostate carcinoma.